Atorvastatin treatment attenuates motor neuron degeneration in wobbler mice

Amyotrophic Lateral Sclerosis

Volumn 10, Issue 5-6, 2009, Pages 405-409

  Iwamoto, Konosuke ^a   Yoshii, Yasuhiro ^a   Ikeda, Ken ^a  

^a TOHO UNIVERSITY OMORI MEDICAL CENTER   (Japan)

Author keywords

Atorvastatin; Motor neuron degeneration; Neuroprotection; Wobbler mouse

Indexed keywords

ATORVASTATIN; CHOLINE ACETYLTRANSFERASE; NEUROPROTECTIVE AGENT;

ANIMAL TISSUE; ARTICLE; BICEPS BRACHII MUSCLE; BODY WEIGHT; CERVICAL SPINAL CORD; CONTROLLED STUDY; DISEASE COURSE; ENZYME ACTIVITY; FORELIMB; MOTONEURON; MOTOR NEURON DISEASE; MOTOR PERFORMANCE; MOUSE; NEUROPROTECTION; NONHUMAN; ONSET AGE; PRIORITY JOURNAL; SYMPTOM; WEIGHT GAIN;

ADMINISTRATION, ORAL; ANIMALS; BODY WEIGHT; CELL SURVIVAL; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MICE; MICE, NEUROLOGIC MUTANTS; MOTOR NEURONS; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR ATROPHY; NERVE DEGENERATION; NEUROMUSCULAR DISEASES; NEUROPROTECTIVE AGENTS; PYRROLES;

EID: 70450158896     PISSN: 17482968     EISSN: 1471180X     Source Type: Journal    
DOI: 10.3109/17482960902870993     Document Type: Article

References (25)

1. Amarenco P, Lavalle'e P, Touboul P-J. Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 2004;3:271-8. (Pubitemid 38510197)
2. Wahner AD, Bronstein JM, Bor Delon YM, Ritz B. Statin use and the risk of Parkinson's disease. Neurology. 2008;70: 1418-22.
3. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G. Decreased prevalence of Alzheimer's disease associated with 3-hydroxyl-3-methylglutaryl- cienzyme A reductase inhibitors. Arch Neurol. 2000;57:1439-43.
4. Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, Schantz A, et al. Statin therapy is associated with reduced neuropathologic changes of Alzheimer's disease. Neurology. 2007; 69:878-85.
5. Kumagai R, Oki C, Muramatsu Y, Kurosaki R, Kato H, Araki T. Pitavastatin, a 3-hydroxyl-3-methylglutaryl-cienzyme A (HMG-CoA) reductase inhibitor, reduces hippocampal damage after transient cerebral ischemia in gerbils. J Neurol Transm. 2004;111:1103-20.
6. Chen J, Zhang C, Jiang H, Li Y, Zhang L, Robin A, et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab. 2005;25:281-90.
7. Selley ML. Simvastatin prevents 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-induced dopamine Depletion and protein tyrosine nitration in mice. Brain Res. 2005;1037:1-6.
8. Youssef S, Stu''eb O, Patarroyo JC, Rulz PC, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature. 2002;420: 78-84.
9. Wang H, Lynch JR, Song P, Yang H-J, Yates RB, Mace B et al. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal Degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol. 2007;206:59-69.
10. Pannu R, Barbosa E, Singh AK, Singh I. Attenuation of acute inflammatory response by atorvastatin after spinal cord injury in rats. J Neurosci Res. 2005;1:340-50.
11. Zinman L, Sa Deghi R, Gawel M, Patton D, Kiss A. Are statin medications safe in patients with ALS. Amyotroph Lateral Scler. 2008;9:223-8.
12. Drory VE, Bronipolsky T, Artamonov I, Nefussy B. Influence of statins treatment on survival in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2008;273:81-3.
13. Ikeda K, Iwasaki Y, Kinoshita M, Marubuchi S, Ono S. T-588, a novel neuroprotective agent, Delays progression of neuromuscular dysfunction in wobbler mouse motor neuron disease. Brain Res. 2000;858:84-91.
14. Scmitt-John T, Drepper C, Mussmann A, Hahn P, Kuhlmann M, Thiel C, et al. Mutation of Vps54 causes motor neuron disease and Defective spermiogenesis in the wobbler mouse. Nat Genet. 2005;37:1213-5.
15. Mitsumoto H, Ikeda K, Klinkosz B, Cedarbaum JM, Wong V, Lindsay RM. Arrest of motor neuron disease in wobbler mice cotreated with CNTF and BDNF. Science. 1994;265: 1107-10.
16. Ikeda K, Kinoshita M, Iwasaki Y, Tagaya N, Shiojima T. Lecithinized superoxi De dismutase retards wobbler mouse motor neuron disease. Neuromusc Disord. 1995;5:383-90.
17. Ikeda K, Iwasaki Y, Kinoshita M. Neuronal nitric oxi De synthase inhibitor, 7-nitroindazole, Delays motor dysfunction and spinal motor neurons Degeneration in the wobbler mouse. J Neurol Sci. 1998;160:9-15.
18. Yoshida M. Potential role of statins in inflammation and atherosclerosis. J Atheroscler Thromb. 2003;10:140-4.
19. Di Napoli P, Taccadi AA, Oliver M, De Caterina R. Statins and stroke: Evi Dence for cholesterol-in Depen Dent effects. Eur Heart J. 2002;23:1908-21.
20. Chen J, Zang ZG, Li Y, Wang Y, Wang L, Jiang H, et al. Statins induces angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53:743-51.
21. Iwasaki Y, Ikeda K, Kano O, Kawabe K, Hirano K. Atorvastatin protects spinal motor neurons from glutamate mediated neurotoxicity. Ann Neurol. 2005;62(Suppl 9):S12.
22. Iwasaki Y, Ikeda K, Kano O, Kawabe K, Murata K. Atorvastatin protects spinal motor neuron Death from axotomy induced neuronal Death. Ann Neurol. 2007; 62(Suppl 11):S61.
23. Mitsumoto H, Bradley WG. Murine motor neuron disease (the wobbler mouse): Degeneration and regeneration of the lower motor neuron. Brain. 1982;105:811-34.
24. Dupuis L, Corcia P, Fergani A, Gonzalez De Aguilar J-L, Bonnefont-Rousselot D, Bittar R, et al. Dyslipi Demia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004-9.
25. Meisler MH, Russ C, Montgomery KT, Greenway M, Ennis S, Hardiman O, et al. Evaluation of the Golgi trafficking protein VPS54 (wobbler) as a candidate for ALS. Amyotroph Lateral Scler. 2008;9:141-8.